Use of injectable hydrogels in the treatment of erectile dysfunction
Injectable hydrogels, made from biocompatible polymers and PDE5 inhibitors, offer a non-invasive, effective treatment for erectile dysfunction by promoting blood flow and reducing side effects, addressing the limitations of current treatments and providing a long-lasting solution for erectile dysfunction.
Patent Information
- Application Number
- PCT/TR2024/050490
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2024-05-16
- Publication Date
- 2024-11-21
AI Technical Summary
Current treatments for erectile dysfunction, such as oral medications and injections, often cause side effects and do not offer a curative approach, and surgical options like penile implants are risky, highlighting the need for a non-invasive, biocompatible, and effective treatment method.
The use of injectable hydrogels, composed of biocompatible polymers like sodium hyaluronate and PDE5 inhibitors, which are administered via injection to promote blood flow and maintain therapeutic effects for 6 to 12 months without the need for surgical intervention or active pharmaceutical ingredients, allowing for combination with other treatments.
The hydrogel formulation provides a safe, comfortable, and long-lasting treatment option that is effective for erectile dysfunction, reducing the frequency of administration and minimizing side effects, while being suitable for use in combination with other therapies and in patients with advanced age-related conditions.
Smart Images

Figure 000001 
Figure 000002 
Figure 000003
Abstract
Description
[0001] USE OF INJECTABLE HYDROGELS IN THE TREATMENT OF ERECTILE DYSFUNCTION
[0002] Field of the Invention
[0003] The present invention relates to the use of injectable hydrogels in the treatment of erectile dysfunction. More specifically, the present invention relates to the development and application of pharmaceutical formulations comprising at least one injectable hydrogel.
[0004] Background of the Invention
[0005] Erectile dysfunction (ED), also known as erectile function disorder, refers to the lack of an erection sufficient for sexual intercourse or premature termination of an erection. Erection is a situation controlled by hormones and developed as a result of the interaction of the nervous system (brain, spinal cord and peripheral nerves) and local factors (penile vascular smooth muscles and surface cells). Several chemical processes occur in the body in response to sexual stimuli. With the contribution of the nerves coming to and from the penis, the blood coming from the arteries accumulates in the spongy bodies that form the structure of the penis as a result of the closure of the veins and causes penile erection. The veins then relax, allowing the accumulated blood to drain and the erection ends. Many organic causes affecting this mechanism prevent the penis from becoming erect.
[0006] The problem of inability to get an erection, which usually manifests itself with advancing age, is a common disorder, especially for individuals aged 40 and over. Erectile dysfunction can sometimes be caused by temporary conditions and sometimes by genetic causes. Therefore, the cause of the disorder and the diagnosis is crucial for determining the treatment modality. One of the requirements for erectile dysfunction to be considered a medical problem is that it must have been present for 6 months or more.
[0007] Usually, oral medication is utilized in treatment of the erectile dysfunction. In this treatment method, the medicine taken orally causes the penis veins to dilate. Phosphodiesterase 5 (PDE5) inhibitors such as sidenafil, tadalafil, vardenafd can be used for this purpose in oral applications. Other major applications also used in the treatment of ED are known as topical, intracavemous, intraurethral and penile injection.
[0008] Current ED pharmacotherapies are symptom-relieving and do not offer a curative approach. Therefore, it is thought that the ideal ED treatment should be disorderspecific drugs with curative purpose. Penile implants which are another option in ED treatment are not welcomed by some patients due to surgical risks. For all these reasons, current research has focused on options that may be curative by affecting the pathophysiology of ED.
[0009] Due to their specific properties such as swellability in water or biological fluids, non-toxicity, biodegradability and biocompatibility, hydrogels are used in a wide range of medical, biological and pharmaceutical applications, including diagnostics, therapy, tissue engineering, bio-nanotechnology and injectable devices such as artificial tissue. Due to the biodegradable nature of hydrogels, they have recently attracted considerable interest in areas such as controlled release of bioactive molecules such as pharmaceutical proteins, drug delivery systems and encapsulation of living cells. Injectable hydrogels are particularly of great interest in the biomedical industry due to their low invasive surgical procedures, tissue adhesion and filling properties. Intemation patent document no WO 1999027905, an application known in the state of the art, discloses an invention which provides a composition for the nasal delivery of a drug suitable for the treatment of erectile dysfunction to a mammal. Herein, the composition is adapted to provide an initial rise in plasma level followed by a sustained plasma level of the drug.
[0010] United States patent document no US20060189695, an application known in the state of the art, discloses an invention which provides an external topical hydrogel preparation comprising a prostaglandin 12 derivative for the prevention or treatment of penile erectile dysfunction. Furthermore, the present invention provides an external topical hydrogel preparation comprising a prostaglandin 12 derivative for treating coital dysfunction.
[0011] In the patent application no W02002011729, an application known in the state of the art, the present invention relates to the discovery that intracavemosal injection of a PDE type V inhibitor such as sildenafd causes penile erection, in the absence of sexual stimulation.
[0012] In the patent application no W02002069966, an application known in the state of the art, the present invention relates to pharmaceutical composition for treatment of erectile dysfunction. The invention also relates to methods of administering compositions for the treatment of erectile dysfunction, including subcutaneous (sub-q), intramuscular (IM), intracavemosal (IC), intravenous (IN) and intraarterial injection.
[0013] In the patent application no W02009058147, an application known in the state of the art, the present invention provides particles for treating erectile dysfunction and for use in restorative procedures. The particles comprise poly[bis(trifluoroethoxy)phosphazene] and / or derivatives thereof, which may be present in an outer coating of the particles. The particles may also include a core having a hydrogel formed from an acrylic -based polymer. Such particles may be loaded to provide localized treatment with an active agent directed at restoration of normal penile erectile function and the treatment of erectile dysfunction. Moreover, such particles may be provided to a user with customized coloration or in various coded colors to indicate differing doses of active agent contained therein.
[0014] Problems such as side effects caused by the active ingredients used, failure to achieve the expected efficacy and increased risk of complications with continuous injections can occur in current drug injection therapies.
[0015] Summary of the Invention
[0016] The objective of the present invention relates to the use of injectable hydrogels in the treatment of erectile dysfunction (ED).
[0017] More specifically, the objective of the present invention relates to the development and application of pharmaceutical formulations comprising at least one injectable hydrogel.
[0018] Another objective of the present invention is to provide a treatment method that is easy to apply, does not require surgical method and is biocompatible in order to eliminate the above-mentioned problems in the said invention.
[0019] The present invention is free of pharmaceutical active ingredients, allowing it to be used in combination with other treatment protocols. Therefore, there are no side effects caused by the active ingredients of the medicine. Another objective of the present invention is to provide a comfortable treatment method for patients, where the frequency of administration (injection) is less than other existing applications. In the present invention, a single injection is effective for 6 to 12 months.
[0020] The invention can also be used in diseases of advanced age (such as coronary artery disease, cardiovascular disease, cerebrovascular disease, high blood pressure).
[0021] Furthermore, an advantage of the present invention is that the polymeric-based hydrogel can act as a drug carrier, enabling the slow release of active ingredients.
[0022] Detailed Description of the Invention
[0023] The objective of the present invention relates to the use of pharmaceutically acceptable and injectable hydrogels in the treatment of erectile dysfunction (ED).
[0024] As used herein, the terms “pharmaceutically acceptable” or “biocompatible” refer to molecules or compounds that do not produce any adverse allergic effect or other undesirable reaction when administered to an animal or human.
[0025] As used herein, the term “excipient” refers to any pharmaceutically acceptable excipient such as a preservative, filler, lubricant, pH adjusting agent, disintegrant, surfactant, solvent, viscosity agent, emulsifier, dispersant, etc. that can be used in pharmaceutical formulation studies.
[0026] As used herein, the term “treatment” refers to the prevention or reduction of the occurrence or progression of, or the complete elimination of, the condition to which the term applies, or of one or more symptoms of that condition. As used herein, the term “therapeutically effective amount” refers to the dose that provides the specific pharmacological response to the patient in need of such treatment.
[0027] Hydrogels consisting of biocompatible polymers used in the treatment disclosed in the said invention comprise at least one of sodium hyaluronate, carboxymethyl cellulose, carboxymethyl chitosan, hydroxypropyl methyl cellulose, chondroitin sulfate, dermatan sulfate, heparan sulfate, polycaprolactone, polyethylene glycol, polylactic acid, polyvinyl alcohol, chitosan, dextran and polyglycolide compounds, or mixtures thereof. In the preferred embodiment of the invention, the hydrogels comprise all of these compounds. In a preferred embodiment of another invention, the hydrogels comprise only sodium hyaluronate.
[0028] The hydrogel polymers disclosed in the present invention may be in crosslinked or non-crosslinked forms.
[0029] The pharmaceutical formulation of the present invention is formulated in such a way that it can be used as a drug for the treatment of erectile dysfunction.
[0030] According to the invention, pharmaceutical formulations comprising at least one injectable hydrogel are developed.
[0031] Pharmaceutical formulations of the present invention can be prepared using standard techniques or manufacturing methods known in the art.
[0032] According to the invention, the therapeutically effective concentration of hydrogel in the formulation is in the range of 10 to 40 mg / ml. According to the invention, the formulation can be administered orally, topically, nasally, intracavemously, intraurethrally and by penile injection. In the preferred embodiment of the invention, the hydrogels are administered by injection with a suitable formulation and dosage form. More specifically, hydrogels are used as pharmaceutical formulations, preferably in liquid dosage form, with at least one excipient during administration by injection. The preferred excipient here is the solvent, which is basically a buffer solution with or without phosphates (deionized water or sterile water). The said dosage forms are liquid forms; they can be gel, cream, emulsion, solution, suspension, etc., and the preferred dosage form in the invention is in gel form.
[0033] The hydrogels of the invention (therapeutically effective amounts to be taken in an administration; dose amount) are adjusted to be effective in achieving the desired therapeutic response for a pharmaceutical form specific to the method of administration. Accordingly, dosages and excipients can be adjusted depending on the desired therapeutic effect, route of administration, desired duration of treatment and other criteria.
[0034] The specific dose level for any patient (human or mouse) can be adjusted on a treatment-specific basis depending on several criteria, including body weight, general health, combination with other drugs and severity.
[0035] In a preferred embodiment of the invention, the formulation may additionally comprise at least one of the active ingredients for the treatment of erectile dysfunction. The active ingredients mentioned here are phosphodiesterase type 5 (PDE5) inhibitors and are at least one or a mixture of active ingredients selected from the group of sildenafil, tadalafil, vardenafil, avanafil and derivatives. At least one or a mixture of these inhibitors can be used in the formulation of the present invention in a concentration range of 0.1-10 mg / ml. These drugs relax the smooth muscles of the veins in the penis and increase blood flow. They do not cause an erection without sexual stimulation.
[0036] In another preferred embodiment of the invention, the formulation may further comprise at least one or any mixture of fibroblast growth factor (FGF), epidermal growth factor (EGF), insulin-like growth factor 1 (IGF-1), transforming growth factor beta 2 (TGF-P2), brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor protein (VEGF), which also help dilate blood vessels. Preferably the invention comprises the VEGF protein and VEGF is a multifunctional protein that promotes angiogenesis. In the formulation of the present invention, VEGF can be used in the range of 0.01 - 1000 ug / ml.
[0037] The formulations of the present invention to be prepared can be filled and prepared in syringes of different volumes of 1-20 ml.
[0038] The use is carried out by injecting the invention in gel form under the fascia with the help of a 27G-30G needle from the lateral dorsum or infero-lateral into the penis with a total of 1-20 ml, providing potential volume and pressure increase during erection and ensuring a healthy erection.
[0039] The production process of the product to be produced preferably in sterile injectable form within the scope of the present invention comprises the following process steps: a) Weighing the raw materials b) Preparing sodium hydroxide (NaOH) solution c) Dissolving polymer d) Adding the cross-linker and mixing e) Performing cross-linking reaction f) Neutralizing the gel g) Purifying the gel h) Homogenizing the final formulation by adding excipients and other active ingredients i) Vacuuming the final mixture j) Filling the gel into syringes k) Sterilizing filled syringes at 124 °C until FO: 12 is reached l) Optically inspecting the sterile syringes m) Labelling the syringes n) Assembling the other components of the labelled syringes o) Blistering the assembled syringes with tyvek and then coding with charge number and expiration date p) Sterilizing closed blister packs with ethylene oxide q) Putting the products in boxes by adding package insert (GPP), patient label and cannula r) Putting the finished product in shipping boxes and storing it in the warehouse.
[0040] Methacrylamide, hydrazide, carbodiimide, divinyl sulfone (DVS), 1,4 -butanediol diglycidyl ether (BDDE) and poly (ethylene glycol) diglycidyl ether were generally used as crosslinking agents. The most widely used agent among these is BDDE. BDDE is a biodegradable substance which is less toxic than other ether- based crosslinking agents. Although hydrogels have long been proven to be safe, the crosslinking agents used are reactive agents that can be cytotoxic and, in some cases, mutagenic. Therefore, the concentration of residual BDDE in the final product is limited by the FDA to < 2 ppm (two parts per million).
Claims
CLAIMS1. A pharmaceutical composition for use in treatment of erectile dysfunction (ED), comprising at least one hydrogel which comprises at least one of sodium hyaluronate, carboxymethyl cellulose, carboxymethyl chitosan, hydroxypropyl methyl cellulose, chondroitin sulfate, dermatan sulfate, heparan sulfate, poly caprolactone, polyethylene glycol, polylactic acid, polyvinyl alcohol, chitosan, dextran and polyglycolide compounds, or mixtures thereof.
2. A formulation according to claim 1, characterized in that it is a hydrogel which comprises all of sodium hyaluronate, carboxymethyl cellulose, carboxymethyl chitosan, hydroxypropyl methyl cellulose, chondroitin sulfate, dermatan sulfate, heparan sulfate, polycaprolactone, polyethylene glycol, polylactic acid, polyvinyl alcohol, chitosan, dextran and polyglycolide compounds.
3. A formulation according to claim 1, characterized in that it is a hydrogel which comprises sodium hyaluronate.
4. A formulation according to claim 2, characterized in that it comprises at least one excipient.
5. A formulation according to claim 4, characterized in that it comprises one or more excipients selected from the group consisting of a pharmaceutically acceptable preservative, fdler, lubricant, pH adjusting agent, disintegrant, surfactant, solvent, viscosity agent, emulsifier, dispersant.
6. A formulation according to claim 5, characterized in that the excipient is a solvent which is any one of deionized water or sterile water.
7. A formulation according to claim 6, characterized in that the dosage form of the formulation is in liquid form.
8. A formulation according to claim 7, characterized in that the dosage form of the formulation is in gel form.
9. A formulation according to claim 8, characterized in that the hydrogel concentration in the formulation is in the range of 10 to 40 mg / ml.
10. A formulation according to claim 9, characterized in that the formulation further comprises an active ingredient.
11. A formulation according to claim 10, characterized in that the active ingredient is at least one or a mixture of sildenafil, tadalafil, vardenafil, avanafil and derivatives thereof.
12. A formulation according to claim 11, characterized in that the formulation further comprises at least one or any mixture of the group consisting of growth factors VEGF, FGF, EGF, IGF-1, TGF- (32, BDNF.
13. A formulation according to claim 12, characterized in that the growth factor is VEGF protein and the protein has a concentration in the range of 0.01 - lOOO ug / ml.
14. A formulation according to claim 13, characterized in that the active ingredient concentration in the formulation is in the range of 0.1 to 10 mg / ml.
15. A formulation according to any one of the preceding claims, characterized in that it is administered by any one of oral, topical, nasal, intracavemous, intraurethral and penile injection routes.
16. A formulation according to claim 15, characterized in that the formulation is administered by injection.
17. A formulation according to any one of the preceding claims, characterized in that a formulation according to any one of claims 1-13 is used in the production of a drug used for the treatment of erectile dysfunction (ED).
18. A formulation according to claim 17, characterized in that the formulation is injected into the penis from the lateral dorsum or infero-lateral under the fascia with a needle.
Citation Information
Patent Citations
Injectable delivery system for heparan-binding growth factors
US20140005111A1
External preparation for improving coital function
WO2005000316A1
Compositions and methods for sustained drug release from an injectable hydrogel
WO2021035217A1
